Carolina García
Oregon Health & Science University(US)
Publications by Year
Research Areas
Phosphodiesterase function and regulation, Cholinesterase and Neurodegenerative Diseases, Histone Deacetylase Inhibitors Research, Alzheimer's disease research and treatments, Neuroscience and Neuropharmacology Research
Most-Cited Works
- → Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease(2012)263 cited
- → Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease(2011)206 cited
- → Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD(2012)185 cited
- → Insulin‐like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice(2014)140 cited
- → Decreased levels of guanosine 3′, 5′‐monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease(2014)108 cited
- → A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice(2016)103 cited
- → Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease(2016)85 cited
- → Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease(2018)67 cited
- → Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease(2015)66 cited
- → Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels(2015)48 cited